**The Role of Cyclooxygenase-2, Epidermal Growth Factor Receptor and Aromatase in Malignant Mesothelioma**

Rossella Galati

78 Malignant Mesothelioma

831-835, ISSN 1347-9032

3368, ISSN 1078-0432

4, (February 2012), pp. 857-864, ISSN 0020-7136

Yarborough, C.M. (2007). The risk of mesothelioma from exposure to chrysotile asbestos. Curr. Opin. Pulm. Med., Vol. 13, No. 4, (July 2007), pp. 334-338, ISSN 1070-5287 Yasumitsu, A., Tabata, C., Tabata, R., Hirayama, N., Murakami, A., Yamada, S., Terada, T., Iida, S., Tamura, K., Fukuoka, K., Kuribayashi, K. & Nakano, T. (2010). Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. *J. Thorac. Oncol.,* Vol. 5, No. 4, (April 2010), pp. 479-483, ISSN 1556-0864 Yoo, S. A., Kwok, S. K. & Kim W. U. (2008). Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritid: prospect for therapeutic

intervention. *Mediators Inflamm*., Vol. 2008, Article ID 129873, ISSN 0962-9351 Yoshida, K. & Miki, Y. (2010). The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. *Cancer Sci.,* Vol. 101, No. 4, (April 2010), pp.

Zebrowski, B. K., Yano, S., Liu, W., Shaheen, R. M., Hicklin, D. J., Putnam, J. B. & Ellis, L. M. (1999). Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. *Clin. Cancer Res.,* Vol. 5, No. 11, (November 1999), pp. 3364-

Ziogas, A. C., Gavalas, N. G., Tsiatas, M., Tsitsilonis, O., Politi, E., Terpos, E., Rodolakis, A., Vlahos, G., Thomakos, N., Haidopoulos, D., Antsaklis, A., Dimopoulos, M. A. & Bamias, A. (2012). VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. *Int. J. Cancer*., Vol. 130, No. Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/50674
